Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia
- 19 January 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 20 (3), 404-409
- https://doi.org/10.1038/sj.leu.2404090
Abstract
We previously reported the results of a double-blind, placebo-controlled study of Filgrastim in patients with de novo AML undergoing induction and consolidation chemotherapy. The study demonstrated that Filgrastim was effective and well tolerated and had no impact on complete remission or survival. We now report follow-up data on these patients, assessing long-term effects with emphasis on prognostic indicators. After a median follow-up of 7 years, 434 (83%) patients were dead, 73 (14%) were alive, and 14 (3%) were lost to follow-up. The proportions of deaths were similar in the Filgrastim (83%) and placebo (84%) groups. No differences in median time to death (1.04 years Filgrastim, 1.13 years placebo; P=0.97) or median disease-free survival (0.86 years Filgrastim, 0.79 years placebo; P=0.52) were evident. Proportional hazard modeling identified age, performance status, and French-American-British subtype as independent predictors for survival (PP=0.005, and P=0.036, respectively), whereas cytogenetic status was not (P=0.118). Filgrastim had no effect on overall survival in any of these subgroup analyses as none of the treatment comparisons were statistically significant. These findings indicate that Filgrastim can be effectively used to support patients with AML undergoing induction and consolidation chemotherapy without worsening long-term disease outcome.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy of granulocyte colony‐stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized studyBritish Journal of Haematology, 2002
- Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemiaLeukemia, 2001
- Chemotherapy for Acute Myelogenous Leukemia in the Elderly With Cytarabine, Mitoxantrone, and Granulocyte-Macrophage Colony-Stimulating FactorAmerican Journal of Clinical Oncology, 2001
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 1999
- Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First RemissionNew England Journal of Medicine, 1998
- Application of myeloid growth factors in the treatment of acute myeloid leukemiaLeukemia, 1997
- Hematopoietic growth factors in acute leukemiaLeukemia, 1997
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaThe New England Journal of Medicine, 1995
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerThe New England Journal of Medicine, 1991